Biosignatures are actively looking for more collaborators in three main areas:

• Clinicians who are interested in validating Biosignatures' exising products in their clinic
• Clinicians who have unmet clinical needs that could be satisfied by new diagnostic product
• Commercial organisations who are interested in marketing the products

Please contact us to find out more.

• Urology Department, Freeman Hospital, Newcastle upon Tyne

  The team at the Freeman are the lead clinical partners on the urology project.
  
  http://www.newcastle-hospitals.org.uk/services/urology.aspx

• Sunderland Royal Hospital

  The team at Sunderland are leading the cross-site validation part of the urology project.
  
  http://www.nhs.uk/Services/Hospitals/Overview/DefaultView.aspx?id=1251

• Newcastle Royal Victoria Infirmary (RVI)

  With Newcastle University, the RVI are the lead clinical partners on the thyroid cancer project.
  
  http://www.newcastle-hospitals.org.uk/hospitals/royal-victoria-infirmary.aspx

• Newcastle University

  With Newcastle Royal Victoria Infirmary, Newcastle University are the lead clinical partners on the thyroid cancer project.
  
  http://www.ncl.ac.uk

• North East Proteome Analysis Facility (NEPAF)

  NEPAF are a key proteomics processing partner.
  
  http://www.nepaf.com/home.html

• Leeds University

  Leeds are a key proteomics processing partner.
  
  http://www.leeds.ac.uk

• Sunderland University

  Biosignatures are working with Sunderland University to explore alternative diagnostic delivery mechanisms, particulary mass spectrometry.
  
  http://www.sunderland.ac.uk

• Transgenomic, Inc.

  Transgenomic were responsible for the proteomic processing in the AD/PD project from their CLIA approved laboratory.
  
  http://www.transgenomic.com

• University of Nebraska

  The University of Nebraska were the clinical lead for the AD/PD study.
  
  http://www.unomaha.edu

• University of Thessaly

  The University of Thessaly provided validation samples from a completely different clinic for the AD/PD study.
  
  http://www.uth.gr/en/

• AstraZeneca

  With AstraZeneca, Biosignatures published the first study showing that the combination of gel based proteomics and advanced software could cope with human blood samples and the levels of biological variability seen in humans.
  http://www.astrazeneca.co.uk

• Novartis Institutes for BioMedical Research (NIBR)

  With NIBR, Biosignatures ran a double blind trial of the Tiger discovery technology. In this trial, the the technology was able to identify the mode of action of antibiotics with 100% accuracy.
  http://www.novartis.com/research/nibr/

• HUPO

  Working with some of the best laboratories in the field of proteomics and alongside NIBR, Biosignatures' then parent company, Nonlinear Dynamics ran the HUPO reproducibility study which proved for the first time 2D gels could generate data that was reproducible cross-lab.
  http://www.hupo.org

• Bio-Rad

  Working with Bio-Rad, Biosignatures' then parent company, Nonlinear Dynamics lead the follow-on reproducibility study which demonstrated how to use standards to enable labs to reproduce each others work.
  http://www.bio-rad.com